KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Total Non-Current Liabilities (2016 - 2025)

Historic Total Non-Current Liabilities for Halozyme Therapeutics (HALO) over the last 14 years, with Q3 2025 value amounting to $1.6 billion.

  • Halozyme Therapeutics' Total Non-Current Liabilities rose 126.76% to $1.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 billion, marking a year-over-year increase of 126.76%. This contributed to the annual value of $1.6 billion for FY2024, which is 205.72% up from last year.
  • Halozyme Therapeutics' Total Non-Current Liabilities amounted to $1.6 billion in Q3 2025, which was up 126.76% from $1.6 billion recorded in Q2 2025.
  • In the past 5 years, Halozyme Therapeutics' Total Non-Current Liabilities ranged from a high of $1.7 billion in Q1 2025 and a low of $896.2 million during Q1 2021
  • In the last 5 years, Halozyme Therapeutics' Total Non-Current Liabilities had a median value of $1.6 billion in 2024 and averaged $1.4 billion.
  • In the last 5 years, Halozyme Therapeutics' Total Non-Current Liabilities surged by 11685.78% in 2021 and then tumbled by 166.47% in 2023.
  • Halozyme Therapeutics' Total Non-Current Liabilities (Quarter) stood at $906.9 million in 2021, then surged by 80.72% to $1.6 billion in 2022, then dropped by 1.66% to $1.6 billion in 2023, then rose by 2.06% to $1.6 billion in 2024, then rose by 0.04% to $1.6 billion in 2025.
  • Its Total Non-Current Liabilities stands at $1.6 billion for Q3 2025, versus $1.6 billion for Q2 2025 and $1.7 billion for Q1 2025.